ICER slashes estimate on cost-effective price for Paxlovid

21 December 2022
money_drugs_scales_large-1-

Months after estimating that a fair US price for Pfizer’s (NYSE: PFE) Paxlovid (nirmatrelvir/ritonavir) would be between $3,600 and $5,800, the Institute for Clinical and Economic Review (ICER) has drastically changed its view.

The cost-effectiveness advisory body issued the earlier valuation of the COVID-19 antiviral treatment in May, since when Paxlovid has become the leading treatment option for the virus.

"The evidence on outpatient treatments for COVID-19 must be viewed as highly sensitive to the evolving landscape of COVID-19 variants and vaccination status"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical